The Technical Analyst
STAAR Surgical Co [STAA]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
STAAR Surgical Co Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.21% $46.90
America/New_York / 18 apr 2024 @ 13:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 291.81 mill |
| EPS: | 0.430 |
| P/E: | 109.07 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 48.87 mill |
| Avg Daily Volume: | 0.733 mill |
| RATING 2024-04-18 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 109.07 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.30x |
| Company: PE 109.07 | industry: PE 33.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$24.82 (-47.08%) $-22.08 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 45.14 - 48.80 ( +/- 3.90%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-14 | Weisner Aimee S | Buy | 1 750 | Common Stock |
| 2024-03-12 | Frinzi Thomas G | Buy | 74 389 | Restricted Stock Units |
| 2024-03-12 | Frinzi Thomas G | Buy | 66 627 | Common Stock Options |
| 2024-03-12 | Foust Warren | Buy | 24 525 | Restricted Stock Units |
| 2024-03-12 | Foust Warren | Buy | 21 966 | Common Stock Options |
| INSIDER POWER |
|---|
| 98.83 |
| Last 95 transactions |
| Buy: 2 389 846 | Sell: 13 779 |
Forecast:
15:37 - $46.94
Live Trading Signals (every 1 min)
Forecast
1: 14:07 - $46.92
Forecast 2: 14:57 - $46.81
Forecast 3: 15:37 - $46.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $46.90 (1.21% ) |
| Volume | 0.128 mill |
| Avg. Vol. | 0.733 mill |
| % of Avg. Vol | 17.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STAA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $30.33 | N/A | Active |
|---|
STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest Press Releases
2024-04-04 07:00:00 - Press Release
Staar Surgical Announces Preliminary Net Sales For First Quarter 2024
Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo icl™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended march 29, 2024, are expected to be in excess of $77 million with u.s. icl sales expected to be $5 million for the quarter. this represents the company's highest quarterly icl sales in the u.s. since the compa.
2024-04-02 07:00:00 - Press Release
Staar Surgical Celebrates Three Million Lens Milestone At Ascrs Meeting, Unveils New Evo Icl Data And Latest Innovation For 2024
Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo icl) for myopia, astigmatism and presbyopia, comes to the american society of cataract and refractive surgery annual meeting (ascrs) in boston from april 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. furthering the momentum behind its flagship product, evo icl, the compa.
2024-03-18 07:00:00 - Press Release
Staar Surgical Celebrates Three Million Implantable Collamer® Lenses
Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo icl™) for myopia, astigmatism and presbyopia, today announced that more than three million icls have been sold globally.1 “we extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our icls for their vision correction as we celebrate our three million lens.
2024-03-12 07:00:00 - Press Release
Staar Surgical Adds Arthur Butcher And Wei Jiang To Board Of Directors
Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (icl) for myopia, astigmatism and presbyopia, today announced the appointment of arthur butcher, executive vice president and group president, medsurg and asia pacific for boston scientific, and wei jiang, retired executive vice president and president of bayer pharmaceuticals region china & apac, to its board of direct.
2024-03-06 07:00:00 - Press Release
Staar Surgical To Participate In Two Upcoming Investor Conferences
Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo icl™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences: oppenheimer healthcare medtech & services conference, tuesday, march 12 sidoti small cap conference, wednesday, march 13 management will also meet with investors in.
Latest News
2024-04-16 06:25:18 - MarketBeat
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
2024-04-05 10:16:08 - Zacks Investment Research
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2024-04-05 10:13:16 - Invezz
What's going on with STAAR Surgical shares?
STAAR Surgical (NASDAQ: STAA) received an upgrade from William Blair on Friday. The stock has been moved from Market Perform to Outperform status.
2024-02-27 15:01:04 - Zacks Investment Research
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-26 19:40:26 - Seeking Alpha
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
2024-02-26 18:31:06 - Zacks Investment Research
Staar Surgical (STAA) Beats Q4 Earnings Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.14 per share a year ago.
2024-02-19 07:00:00 - Business Wire
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to dis.
2023-12-17 12:35:39 - InvestorPlace
7 Stocks with Strong Insider Buying: December 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.
2023-11-01 22:23:02 - Seeking Alpha
STAAR Surgical Company (STAA) Q3 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentlemen.
2023-10-25 14:53:00 - Market Watch
These healthcare stocks should come to life as boomers live their golden years
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.